Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciltacabtagene autoleucel + dexamethasone + efineptakin alfa
- Development stage
- Unknown
- Lead developer
- NeoImmuneTech
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
BCMA-targeted CAR T cells + dexamethasone + NT-I7 is an investigational combination therapy being evaluated for the treatment of relapsed and refractory multiple myeloma. The regimen consists of ciltacabtagene autoleucel (a BCMA-directed CAR T-cell therapy), the corticosteroid dexamethasone, and NT-I7 (efineptakin alfa), a long-acting recombinant human interleukin-7 (IL-7) fusion protein. The therapeutic strategy utilizes dexamethasone to upregulate the expression of the IL-7 receptor alpha (IL-7Rα) on the surface of the CAR T cells, thereby sensitizing them to IL-7 signaling. Subsequent administration of NT-I7 leverages this increased receptor density to promote the expansion, metabolic fitness, and long-term persistence of the CAR T cells in the tumor microenvironment. This combination aims to overcome the common challenge of limited CAR T-cell durability and prevent early relapse in myeloma patients.
- Other names
- BCMA-targeted CAR T cells + dexamethasone + NT-I7Cilta-cel + dex + NT-I7
02
Targets
IL2RG (Interleukin-2 receptor gamma subunit)GR (Glucocorticoid receptor)BCMA (B-cell maturation antigen)FCGRT (Neonatal crystallizable fragment receptor)IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on ciltacabtagene autoleucel + dexamethasone + efineptakin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciltacabtagene autoleucel + dexamethasone + efineptakin alfa.